Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a gene editing company, reported its share and voting rights on November 30, 2021, with a total of 45,477,810 shares and 51,079,282 voting rights. The company focuses on CAR-T immunotherapies and gene editing technologies for cancer treatment. Headquartered in Paris, Cellectis is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The firm targets various cancers, utilizing its TALEN® technology and the PulseAgile system, aiming to address unmet medical needs. For more details, visit www.cellectis.com.

Positive

• Cellectis reports a total of 45,477,810 shares and 51,079,282 voting rights as of November 30, 2021.
• The company is pioneering CAR-T immunotherapies and gene editing technologies.
• Cellectis focuses on addressing unmet medical needs in oncology.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) --  

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
11/30/2021	45,477,810	51,079,282

About Cellectis
Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomial storage diseases.

Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com   
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

Investor Relation contact:
Arthur Stril, Chief Business Officer, +33684439609, investors@cellectis.com 

Sandya von der Weid, Associate Director, LifeSci Advisors, +41786800538, svonderweid@lifesciadvisors.com

Attachment

• Voting_Rights_PR_November_EN_docx

FAQ

What is the total number of shares for Cellectis as of November 30, 2021?

Cellectis has a total of 45,477,810 shares as of November 30, 2021.

How many voting rights does Cellectis have as of the latest report?

Cellectis has 51,079,282 voting rights as of November 30, 2021.

What are Cellectis' primary areas of focus in gene editing?

Cellectis focuses on CAR-T immunotherapies and developing gene editing products for cancer treatment.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under ALCLS.